ID   NTERA-2
AC   CVCL_0034
SY   NTera-2; Ntera-2; NTera 2; NTERA2; NTera2; N-Tera-2; NT-2; NT2
DR   BTO; BTO:0000891
DR   CLO; CLO_0008208
DR   EFO; EFO_0002959
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472969
DR   CCRID; 1101HUM-PUMC000019
DR   ChEMBL-Cells; CHEMBL3308505
DR   ChEMBL-Targets; CHEMBL614205
DR   Cosmic; 821809
DR   Cosmic; 2439936
DR   Cosmic; 2560242
DR   Cosmic; 2806394
DR   Cosmic; 2807075
DR   DSMZ; ACC-527
DR   DSMZCellDive; ACC-527
DR   EGA; EGAS00001000610
DR   IBRC; C10509
DR   PharmacoDB; NTERA2_1167_2019
DR   PRIDE; PXD030251
DR   RSCB; RSCB0150
DR   Wikidata; Q17092091
RX   PubMed=3293662;
RX   PubMed=6694356;
RX   PubMed=16919167;
RX   PubMed=25485619;
RX   PubMed=35084545;
WW   https://en.wikipedia.org/wiki/NTERA-2
WW   https://www.proteinatlas.org/learn/cellines
CC   Population: Caucasian.
CC   Doubling time: ~50-60 hours (DSMZ).
CC   HLA typing: A*01; B*08; C*07; DQB1*02; DRB1*03; DRB3*01 (PubMed=16919167).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Derived from metastatic site: Lung.
ST   Source(s): DSMZ; PubMed=16919167; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 11,12,13
ST   D18S51: 14
ST   D19S433: 14
ST   D21S11: 30,31
ST   D2S1338: 22,25
ST   D3S1358: 16
ST   D5S818: 9,12
ST   D7S820: 10,12
ST   D8S1179: 13,15
ST   FGA: 23
ST   Penta D: 12,13
ST   Penta E: 5,14
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 18,19
DI   NCIt; C3752; Embryonal carcinoma
DI   ORDO; Orphanet_180226; Embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_2777 ! Tera-2
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-06-22; Version: 25
//
RX   PubMed=3293662; DOI=10.1016/0304-419X(88)90003-0;
RA   Andrews P.W.;
RT   "Human teratocarcinomas.";
RL   Biochim. Biophys. Acta 948:17-36(1988).
//
RX   PubMed=6694356;
RA   Andrews P.W., Damjanov I., Simon D., Banting G.S., Carlin C.R.,
RA   Dracopoli N.C., Fogh J.;
RT   "Pluripotent embryonal carcinoma clones derived from the human
RT   teratocarcinoma cell line Tera-2. Differentiation in vivo and in
RT   vitro.";
RL   Lab. Invest. 50:147-162(1984).
//
RX   PubMed=16919167; DOI=10.1186/1741-7007-4-28;
RA   Josephson R., Sykes G., Liu Y., Ording C.J., Xu W.-N., Zeng X.-M.,
RA   Shin S., Loring J.F., Maitra A., Rao M.S., Auerbach J.M.;
RT   "A molecular scheme for improved characterization of human embryonic
RT   stem cell lines.";
RL   BMC Biol. 4:28.1-28.13(2006).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=35084545; DOI=10.1007/s00345-022-03936-1;
RA   Fichtner A., Bohnenberger H., Elakad O., Richter A., Lenz C., Oing C.,
RA   Strobel P., Kueffer S., Nettersheim D., Bremmer F.;
RT   "Proteomic profiling of cisplatin-resistant and cisplatin-sensitive
RT   germ cell tumour cell lines using quantitative mass spectrometry.";
RL   World J. Urol. 40:373-383(2022).
//